Long term oncology outcome of Radio frequency ablation (RFA) for T1 renal cell carcinoma
BAUS ePoster online library. Steen B. 06/25/19; 259583; P8-7
Mr. Benjamin Steen
Mr. Benjamin Steen
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
Objective
To describe oncology outcomes and complications with radiofrequency ablation (RFA) for T1 renal cell carcinoma in a centre with 14-year experience

Method
Retrospective study of 89 consecutive patients from 2005 to 2013 who underwent RFA. Those with metastatic disease at time of treatment, incomplete follow up, proven benign pathology, genetic underlying genetic pre-disposition were excluded. 76 patients with 80 tumours met the inclusion criteria. Data was collected on; demographics, oncological outcomes and complications. Primary outcome measures were disease free survival and cancer specific survival at 5 and 8 years.

RESULTS

Median follow up was 83 months. We demonstrate an 89% 5-year disease free survival (DFS) and 79% 8year DFS. Median time to progression was 63months. When classified by tumour size no significant difference was seen in 5 or 8-year DFS. Cancer specific survival was demonstrated as 98% at 5 years and 96% at 8 years – all cancer related deaths had an initial tumour of >3cm diameter. The median time to progression for secondary failure was 50.7 months. Two Clavien-Dindo Grade 2 complications were encountered in the series.

Outcome
RFA produces comparable long-term oncological outcomes to other modalities for T1 tumours with a low complication rate
Objective
To describe oncology outcomes and complications with radiofrequency ablation (RFA) for T1 renal cell carcinoma in a centre with 14-year experience

Method
Retrospective study of 89 consecutive patients from 2005 to 2013 who underwent RFA. Those with metastatic disease at time of treatment, incomplete follow up, proven benign pathology, genetic underlying genetic pre-disposition were excluded. 76 patients with 80 tumours met the inclusion criteria. Data was collected on; demographics, oncological outcomes and complications. Primary outcome measures were disease free survival and cancer specific survival at 5 and 8 years.

RESULTS

Median follow up was 83 months. We demonstrate an 89% 5-year disease free survival (DFS) and 79% 8year DFS. Median time to progression was 63months. When classified by tumour size no significant difference was seen in 5 or 8-year DFS. Cancer specific survival was demonstrated as 98% at 5 years and 96% at 8 years – all cancer related deaths had an initial tumour of >3cm diameter. The median time to progression for secondary failure was 50.7 months. Two Clavien-Dindo Grade 2 complications were encountered in the series.

Outcome
RFA produces comparable long-term oncological outcomes to other modalities for T1 tumours with a low complication rate
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies